Riskpilot← Back to searchSign inGet full accessIRL 752 AB
ABActiveOrg 5590418371Arvid Wallgrens Backe 20Research and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2024
SEK 0
EBITDA margin
—
+43% vs 2023
Equity ratio
27.6%
Financial strength
Net profit 2024
SEK -34,9M
+43% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -34,9M | +43% |
| Net profit | SEK -34,9M | +43% |
| Total assets | SEK 2,9M | +1% |
| Equity | SEK 815K | +391% |
| Employees | 0 | — |
Legal name
IRL 752 AB
Org number
5590418371
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15 december 2015
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska på kommersiella grunder bedriva forskning och utveckling av nya läkemedel, för behandling av neurologiska och psykiatriska sjukdomstillstånd, med huvudsaklig verkan på det centrala nervsystemets funktioner samt äga fast egendom, förvalta och utveckla immateriella rättigheter och bedriva därmed förenlig verksamhet.
Address
Arvid Wallgrens Backe 20
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −1 | — | −22 782 | −37 505 | −16 238 | −17 550 | −42 151 | −61 136 | −34 863 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −1 | 0 | −22 782 | −37 505 | −16 238 | −17 550 | −42 151 | −61 136 | −34 863 |
| Net financials | — | — | — | — | — | — | −6 | 36 | 10 |
| Profit before tax | −1 | 0 | −22 782 | −37 505 | −16 238 | −17 550 | −42 157 | −61 100 | −34 853 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 | 0 | −22 782 | −37 505 | −16 238 | −17 550 | −42 157 | −61 100 | −34 853 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 49 | 849 | 3 616 | 3 374 | 3 269 | 12 360 | 2 964 | 2 908 | 2 949 |
| Equity | 49 | 49 | 3 616 | 211 | 973 | 423 | 266 | 166 | 815 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 800 | 0 | 3 163 | 2 297 | 11 937 | 2 698 | 2 743 | 2 134 |
| Total debt | — | 800 | — | 3 163 | 2 297 | 11 937 | 2 698 | 2 743 | 2 134 |
EBITDA margin
-3486300000.0%
This company
15.8%
Market median
-22065189973% vs market
20162024
Equity ratio
27.6%
This company
38.2%
Market median
-28% vs market
20162024
Return on equity
-4276.4%
This company
18.4%
Market median
-23341% vs market
20162024
Net profit margin
-3485300000.0%
This company
8.1%
Market median
-43028395162% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
2.62×
This company
0.62×
Market median
-323% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-12-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SU Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2025 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Integrative Research Laboratories Sweden AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
IRLAB Therapeutics AB
IRL 752 AB Board members of IRL 752 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sofia Ulrika Ramsvik | Chief Auditor | 0 companies |
| Erik Viktor Siewertz | Deputy Board Member | 0 companies |
| Gunnar Olof Olsson | Chairman | 0 companies |
| Maria Cecilia Tivert Stenberg | Deputy Board Member | 0 companies |
| Ross Nicholas Waters | Board of Directors | 0 companies |
| Anna Kristina Torfgård | Chairman | 0 companies |
| Jan Anders Vedin | Chairman | 0 companies |